Table 2.
Multiple regression analysis of progression free survival factors by multivariable analysis.
| Analyze | Univariate | Multivariate | ||
|---|---|---|---|---|
| Result | HR (95% CI for HR) | p-Value | HR (95% CI for HR) | p-Value |
| GE score PFS + prediction | 0.55 (0.32–0.95) | 0.032 | 0.5 (0.28–0.9) | 0.025 |
| CA 19–9 (U/mL) | 1 (1–1) | 0.47 | ||
| Albumin (g/L) | 1 (0.96–1) | 0.81 | ||
| QLQ-C30 | 1 (1–1) | 0.038 | 1.02 (1.0–1.04) | 0.026 |
| Body mass index | 0.99 (0.93–1.1) | 0.76 | ||
| ECOG PS | 2 (1–3.8) | 0.045 | 1.6 (0.8–3.1) | 0.17 |
| Monocyte count (per µL) | 0.73 (0.29–1.8) | 0.49 | ||
| Tumor localization | ||||
| head | 1.2 (0.69–2.1) | 0.52 | ||
| body | 1.1 (0.64–1.9) | 0.7 | ||
| tail | 1.5 (0.84–2.8) | 0.16 | ||
| Clinical classification | 0.7 (0.35–1.4) | 0.32 | ||
Abbreviations: QLQ-C30; European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 item global health status. GE; gene expression. CA19–9; carbohydrate antigen 19–9. ECOG PS; Eastern Cooperative Oncology Group Performance Status.